14,15-dihydro-eburnamenine | 47122-74-7

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - Eburnan型生物碱
• 英文名称: 14,15-dihydro-eburnamenine
• 英文别名: dihydro-eburnamenine；(+/-)-Dihydroepieburunamenine；d,l-Dihydroeburnamenin；Dihydro-eburnamenin；14,15-Dihydroeburnamenine；15-ethyl-1,11-diazapentacyclo[9.6.2.02,7.08,18.015,19]nonadeca-2,4,6,8(18)-tetraene
• CAS: 47122-74-7；53946-80-8；53955-88-7；65026-49-5；96896-20-7；124222-39-5
• 化学式: C₁₉H₂₄N₂
• 分子量: 280.413
• InChiKey: VYXFLLCQSGSEMS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  8.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• [EN] ANALOGS OF VINCAMINE AND USES THEREOF<br/>[FR] ANALOGUES DE LA VINCAMINE ET UTILISATIONS DE CEUX-CI
  申请人：UNIV FLORIDA

  公开号：WO2018151951A1

  公开（公告）日：2018-08-23

  The present disclosure provides compounds of any one of Formulae (I'), (I), (IA), (II'), (II), (IIA), (IIIA), (III"), (III'), (III), (IIIA), (IV), (V'), (V), (VI), (VII), (VIII'), (VIII), (ΙΧ'), (IX), and (X). The compounds described herein may be useful in treating and/or preventing a broad range of diseases (e.g., proliferative disease (e.g., cancers (e.g., non-small cell lung cancer, or glioma), inflammatory diseases, autoimmune diseases), CNS disorder (e.g., drug addiction), metabolic disorder (e.g., diabetes), or infectious disease (e.g., bacterial infection or parasitic infection (e.g., malaria))). Also provided in the present disclosure are pharmaceutical compositions, methods of synthesis of a compound described herein, kits, methods, and uses including or using a compound described herein.

  本公开提供了任一式(I')、(I)、(IA)、(II')、(II)、(IIA)、(IIIA)、(III")、(III')、(III)、(IIIA)、(IV)、(V')、(V)、(VI)、(VII)、(VIII')、(VIII)、(ΙΧ')、(IX)和(X)的化合物。本文所述的化合物可能有助于治疗和/或预防广泛范围的疾病（例如增殖性疾病（例如癌症（例如非小细胞肺癌或胶质瘤）、炎症性疾病、自身免疫疾病）、中枢神经系统疾病（例如药物成瘾）、代谢性疾病（例如糖尿病）或传染病（例如细菌感染或寄生虫感染（例如疟疾）））。本公开还提供了药物组合物、本文所述化合物的合成方法、试剂盒、方法和用途，包括或使用本文所述的化合物。
• Analogs of vincamine and uses thereof
  申请人：University of Florida Research Foundation, Incorporated

  公开号：US11130764B2

  公开（公告）日：2021-09-28

  The present disclosure provides compounds of any one of Formulae (I′), (I), (IA), (II′), (II), (IIA), (IIIA), (III″), (III′), (III), (IIIA), (IV), (V′), (V), (VI), (VII), (VIII′), (VIII), (IX′), (IX), and (X). The compounds described herein may be useful in treating and/or preventing a broad range of diseases (e.g., proliferative disease (e.g., cancers (e.g., non-small cell lung cancer, or glioma), inflammatory diseases, autoimmune diseases), CNS disorder (e.g., drug addiction), metabolic disorder (e.g., diabetes), or infectious disease (e.g., bacterial infection or parasitic infection (e.g., malaria))). Also provided in the present disclosure are pharmaceutical compositions, methods of synthesis of a compound described herein, kits, methods, and uses including or using a compound described herein.

  (III″）、（III′）、（III）、（IIIA）、（IV）、（V′）、（V）、（VI）、（VII）、（VIII′）、（VIII）、（IX′）、（IX）和（X）。本文所述化合物可用于治疗和/或预防多种疾病（如增殖性疾病（如癌症（如非小细胞肺癌或胶质瘤）、炎症性疾病、自身免疫性疾病）、中枢神经系统疾病（如药物成瘾）、代谢性疾病（如糖尿病）或传染性疾病（如细菌感染或寄生虫感染（如疟疾）））。本公开还提供了药物组合物、本文所述化合物的合成方法、试剂盒、方法以及包括或使用本文所述化合物的用途。
• METHOD AND COMPOSITIONS FOR TREATMENT OR PREVENTION OF INFLAMMATORY CONDITIONS
  申请人：Yan Chen

  公开号：US20100221340A1

  公开（公告）日：2010-09-02

  Pharmaceutical compositions and methods for treating or preventing an inflammatory condition in a patient are disclosed. The pharmaceutical compositions and methods include the use of vincamine or a vincamine derivative, either alone or in combination with one or more additional therapeutic agents, including a steroid (preferably a corticosteroid), an angiotensin II receptor (type 1) antagonist, an angiotensin-converting enzyme (ACE) inhibitor, and a non-steroidal anti-inflammatory drug.
• Method and Compositions for Treatment or Prevention of Inflammatory Conditions
  申请人：Yan Chen

  公开号：US20140296273A1

  公开（公告）日：2014-10-02

  Pharmaceutical compositions and methods for treating or preventing an inflammatory condition in a patient are disclosed. The pharmaceutical compositions and methods include the use of vincamine or a vincamine derivative, either alone or in combination with one or more additional therapeutic agents, including a steroid (preferably a corticosteroid), an angiotensin II receptor (type 1) antagonist, an angiotensin-converting enzyme (ACE) inhibitor, and a non-steroidal anti-inflammatory drug.
• US9241932B2
  申请人：——

  公开号：US9241932B2

  公开（公告）日：2016-01-26

表征谱图